Does the location of inflammatory lesions in the gastrointestinal tract determine the clinical course of Crohn’s disease?
References
- Arora U., Kedia S., Garg S., Bopanna S., Jain S., Yadav D.P., Goyal S., Gupta V., Sahni P., Pal S., Dash N.R., Madhusudhan K.S., Sharma R., Makharia G., Ahuja V.: Colonic Crohn’s disease is associated with less aggressive disease course than ileal or ileocolonic disease. Dig. Dis. Sci., 2018; 63: 1592–1599
- Bartnik W.: Choroba Crohna jelita grubego. Pol. Arch. Med. Wewn., 1971; 47: 383–388
- Bartnik W.: Inflammatory bowel disease – polish contribution. J. Physiol. Pharmacol. 2003; 54 Suppl., 3: 205–210
- Cleynen I., Boucher G., Jostins L., Schumm P., Zeissig S., Ahmad T., Andersen V., Andrews J.M., Annese V., Brand S., Brant S.R., Cho J.C., Daly M.J., Dubinsky M., Duerr R.H., et al.: International Inflammatory Bowel Disease Genetics Consortium. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: A genetic association study. Lancet, 2016; 387: 156–167
- Cleynen I., González J.R., Figueroa C., Franke A., McGovern D., Bortlík M., Crusius B.JA., Vecchi M., Artieda M., Szczypiorska M., Bethge J., Arteta D., Ayala E., Danese S., Hogezand R., et al.: Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBD European Project. Gut, 2013; 62: 1556–1565
- Crohn B.B., Ginzburg L., Oppenheimer G.D.: Regional ileitis; a pathologic and clinical entity. JAMA, 1932; 99; 1323–1329
- Daperno M., D’Haens G., Van Assche G., Baert F., Bulois P., Maunoury V., Sostegni R., Rocca R., Pera A., Gevers A., Mary Y.V., Colombel J.F., Rutgeerts P.: Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: The SES-CD. Gastrointest. Endosc., 2004; 60: 505–512
- Dulai P.S., Singh S., Casteele N.V., Boland B.S., Rivera-Nieves J., Ernst P.B., Eckmann L., Barrett K.E., Chang J.T., Sandborn W.J.: Should we divide Crohn’s disease into ileum-dominant and isolated colonic diseases? Clin. Gastroenterol. Hepatol., 2019; 17: 2634–2643
- Fiocchi C.: Inflammatory bowel disease pathogenesis: Where are we? J. Gastroenterol. Hepatol., 2015; 30, Suppl. 1: 12–28
- Guizzetti L., Zou G., Khanna R., Dulai P.S., Sandborn W.J., Jairath V., Feagan B.G.: Development of clinical prediction models for surgery and complications in Crohn’s disease. J. Crohns. Colitis, 2018; 12: 167–177
- Hancock L., Beckly J., Geremia A., Cooney R., Cummings F., Pathan S., Guo C., Warren B., Mortensen N., Ahmad T., Jewell D.: Clinical and molecular characteristics of isolated colonic Crohn’s disease. Inflamm. Bowel Dis., 2008; 14: 1667–1677
- Li D., Haritunians T., Landers C., Potdar A.P., Yang S., Huang H., Schumm P., Daly M., Targan S., McGovern D.: Late-onset Crohn’s disease is a subgroup distinct in genetic and behavioral risk factors with UC-like characteristics. Inflamm. Bowel Dis., 2018; 24: 2413–2422
- Lockhart-Mummery H.E., Morson B.C.: Crohn’s disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut, 1960; 1: 87–105
- Łodyga M., Eder P., Bartnik W., Gonciarz M., Kłopocka M., Linke K., Małecka-Panas E., Radwan P., Rydzewska G.: Guidelines for the management of Crohn’s disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. Gastroenterology Rev., 2013; 7: 317–338
- Mulder D.J., Noble A.J., Justinich C.J., Duffin J.M.: A tale of two diseases: The history of inflammatory bowel disease. J. Crohns Colitis, 2014; 8: 341–348
- Parkes G.C., Whelan K., Lindsay J.O.: Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J. Crohns Colitis, 2014; 8: 717–725
- Sandborn W.J., Feagan B.G., Hanauer S.B., Lochs H., Löfberg R., Modigliani R., Present D.H., Rutgeerts P., Schölmerich J., Stange E.F., Sutherland L.R.: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology, 2002; 122: 512–530
- Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F.: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006; 55: 749–753
- Solberg I.C., Cvancarova M., Vatn M.H., Moum B.: Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn’s disease. Inflamm. Bowel Dis., 2014; 20: 60–68
- Solberg I.C., Vatn M.H., Hřie O., Stray N., Sauar J., Jahnsen J., Moum B., Lygren I.: Clinical course in Crohn’s disease: Results of a Norwegian population based ten-year follow-up study. Clin. Gastroenterol. Hepatol., 2007; 5: 1430–1438
- Subramanian S., Ekbom A., Rhodes J.M.: Recent advances in clinical practice: A systematic review of isolated colonic Crohn’s disease: The third IBD? Gut, 2017; 66: 362–381
- Wells C.: Ulcerative colitis and Crohn’s disease. Ann. R. Coll. Surg. Engl., 1952; 11: 105–120
- Xu Y., Guo Z., Cao L., Xie T., Shen W., Li Y., Gong J., Zhu W.: Isolated colonic Crohn’s disease is associated with a reduced response to exclusive enteral nutrition compared to ileal or ileocolonic disease. Clin. Nutr., 2019; 38: 1629–1635
- Zhang Y.Z., Li Y.Y.: Inflammatory bowel disease: Pathogenesis. World J. Gastroenterol., 2014; 20: 91–99
DOI: https://doi.org/10.5604/01.3001.0014.6581 | Journal eISSN: 1732-2693
Language: English
Page range: 12 - 17
Submitted on: Feb 10, 2020
Accepted on: Sep 23, 2020
Published on: Jan 18, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2021 Julia Banasik, Milena Padysz, Monika Pawłowicz, Anita Gąsiorowska, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.